Table 1.
Characteristics of human subjects used in this study
| Patients (142) | Controls (83) | |||
|---|---|---|---|---|
| Median age (range) | 35 (20 to 74) | 32 (19 to 61) | ||
| number | percentage | number | percentage | |
| Females | 129 | 91% | 55 | 66% |
| Males | 13 | 9% | 28 | 34% |
| Caucasians | 62 | 43% | 49 | 60% |
| African Americans | 57 | 40% | 18 | 22% |
| Hispanics | 20 | 14% | 2 | 2% |
| Asians | 1 | 1% | 8 | 10% |
| Mixed | 4 | 3% | 4 | 5% |
| PBX1-a | 30 | 33% | 28 | 56% |
| PBX1-a/d | 25 | 27% | 14 | 28% |
| PBX1-d | 37 | 40% | 8 | !6% |
| Medications | ||||
| Steroids | 62 | 42% | ||
| No steroid | 85 | 58% | ||
| Mycophenolate mofetil | 69 | 47% | ||
| Methotrexate | 7 | 5% | ||
| Azathioprine | 17 | 12% | ||
| Cyclophosphamide | 2 | 1% | ||
| Abatacept | 4 | 3% | ||
| No immunosuppressive | 47 | 32% | ||
| Untreated | 30 | 21% | ||
| Disease activity | ||||
| Inactive | 58 | 48% | ||
| Active non-renal | 14 | 12% | ||
| Active renal | 49 | 40% | ||